58,059 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Twin Lakes Capital Management LLC

Twin Lakes Capital Management LLC purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 58,059 shares of the company’s stock, valued at approximately $7,117,000. Protagonist Therapeutics comprises 2.7% of Twin Lakes Capital Management LLC’s holdings, making the stock its 6th biggest holding. Twin Lakes Capital Management LLC owned 0.09% of Protagonist Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Royal Bank of Canada grew its holdings in shares of Protagonist Therapeutics by 30.6% in the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock worth $482,000 after acquiring an additional 2,334 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Protagonist Therapeutics by 0.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock valued at $1,810,000 after purchasing an additional 348 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Protagonist Therapeutics by 283.6% during the first quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock valued at $6,493,000 after purchasing an additional 99,269 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Protagonist Therapeutics in the 2nd quarter valued at $987,000. Finally, Guggenheim Capital LLC boosted its position in shares of Protagonist Therapeutics by 1.6% in the 2nd quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock valued at $1,062,000 after purchasing an additional 303 shares during the period. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Price Performance

Shares of PTGX opened at $144.33 on Friday. The business’s 50-day moving average is $138.51 and its 200-day moving average is $112.49. The company has a market capitalization of $9.34 billion, a price-to-earnings ratio of 140.13 and a beta of 1.78. Protagonist Therapeutics, Inc. has a fifty-two week low of $54.50 and a fifty-two week high of $160.81.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.27 by $0.02. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The business had revenue of $213.47 million during the quarter, compared to analysts’ expectations of $212.03 million. Protagonist Therapeutics’s quarterly revenue was up 3746.8% on a year-over-year basis. Equities research analysts expect that Protagonist Therapeutics, Inc. will post 4.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Dinesh V. Ph D. Patel sold 34,239 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $148.52, for a total transaction of $5,085,176.28. Following the transaction, the chief executive officer directly owned 523,478 shares in the company, valued at $77,746,952.56. The trade was a 6.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William D. Waddill sold 9,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the transaction, the director owned 7,825 shares in the company, valued at approximately $922,880.50. This represents a 53.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 118,000 shares of company stock valued at $16,921,379 in the last three months. Company insiders own 5.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on PTGX shares. Citizens Jmp boosted their price objective on Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. TD Cowen reissued a “buy” rating on shares of Protagonist Therapeutics in a research report on Wednesday, July 1st. UBS Group upgraded shares of Protagonist Therapeutics to a “buy” rating in a report on Monday, August 10th. Weiss Ratings upgraded shares of Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Finally, The Goldman Sachs Group raised shares of Protagonist Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $110.00 to $186.00 in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $140.53.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.